Compare Cassava Sciences Inc (FLNA) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs SiTime Corporation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while SiTime Corporation trades at $575.79 (market cap $18.34B). The key difference: SiTime Corporation is far larger — about 345.1× Cassava Sciences Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SITM | |
|---|---|---|
Market Cap | $53.14M | $18.34B |
Sector | Health | Technology |
52-Week High | $4.64 | $901.60 |
52-Week Low | $1.09 | $190.16 |
Enterprise Value | -$33.43M | $17.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
SITM trades at $583.36, down 6.49% today, amid a bearish technical signal. The stock shows strong earnings beats in recent quarters but negative profitability margins. Recent news includes the completion of Renesas' timing business acquisition and strong AI-driven revenue growth. Cash flow trends indicate heavy investment activity in 2025, with a projected improvement in 2026.
Outlook is mixed; analyst consensus is strongly bullish with a $825 price target, but high valuation ratios and negative margins pose risks. The stock's near-term direction may hinge on Q2 2026 earnings due August 5, 2026, and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
